Vertex Pharmaceuticals (VRTX) Revenue Growth (5y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.61% |
| Dec 31, 2025 | 14.40% |
| Sep 30, 2025 | 14.87% |
| Jun 30, 2025 | 14.23% |
| Mar 31, 2025 | 12.83% |
| Dec 31, 2024 | 79.61% |
| Sep 30, 2024 | 23.89% |
| Jun 30, 2024 | 22.96% |
| Mar 31, 2024 | 25.67% |
| Dec 31, 2023 | 23.68% |
| Sep 30, 2023 | 25.92% |
| Jun 30, 2023 | 27.08% |
| Mar 31, 2023 | 29.95% |
| Dec 31, 2022 | 28.72% |
| Sep 30, 2022 | 32.20% |
| Jun 30, 2022 | 32.19% |
| Mar 31, 2022 | 24.03% |
| Dec 31, 2021 | 35.21% |
| Sep 30, 2021 | 37.10% |
| Jun 30, 2021 | 33.33% |
| Mar 31, 2021 | 34.07% |
| Dec 31, 2020 | 31.98% |
| Sep 30, 2020 | 38.44% |
| Jun 30, 2020 | 55.80% |
| Mar 31, 2020 | 63.20% |
| Dec 31, 2019 | 1.51% |
| Sep 30, 2019 | 47.27% |
| Jun 30, 2019 | 50.40% |
| Mar 31, 2019 | 48.61% |
| Dec 31, 2018 | 46.53% |
| Sep 30, 2018 | 28.76% |
| Jun 30, 2018 | 24.17% |
| Mar 31, 2018 | 14.31% |
| Dec 31, 2017 | 14.30% |
| Sep 30, 2017 | 11.47% |
| Jun 30, 2017 | 5.40% |
| Mar 31, 2017 | 13.75% |
| Dec 31, 2016 | -4.03% |
| Sep 30, 2016 | -0.48% |
| Mar 31, 2016 | 40.13% |
| Dec 31, 2015 | 44.06% |
| Sep 30, 2015 | 66.28% |
| Jun 30, 2015 | 39.34% |
| Mar 31, 2015 | 42.30% |
| Dec 31, 2014 | 33.66% |
| Sep 30, 2014 | 40.59% |
| Jun 30, 2014 | 45.03% |
| Mar 31, 2014 | 37.64% |